DelveInsight has launched a new report on Hemophilia B Market Insights, Epidemiology and Market Forecast-2030
DelveInsight’s “Hemophilia B – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Hemophilia B, historical and forecasted epidemiology as well as the Hemophilia B market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Hemophilia B market report provides current treatment practices, emerging drugs, Hemophilia B market share of the individual therapies, current and forecasted Hemophilia B market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Hemophilia B treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
According tothe Centers for Disease Control and Prevention, Hemophilia B is a genetic disorder caused by missing or defective Factor IX clotting protein. With the lack of this, the blood cannot clot properly to control bleedinglike hemophilia A, it is also inherited and is caused by a spontaneous genetic mutation in one-third of the cases. Individuals with hemophilia B do not bleed faster than unaffected individuals, they bleed longer.
Request for :- free sample page
Epidemiology
The Hemophilia B epidemiology division provide insights about historical and current Hemophilia B patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Reports Key facts:-
1. According to the World Federation of Hemophilia (WFH), the total number of cases around the World for Hemophilia B in 2018 was 34,289.
2. Centers for Disease Control and Preventionstates Hemophilia occurs in about 1 of every 5,000 male births and Hemophilia A is about four times as common as hemophilia B, and about half of those affected have a severe form. Hemophilia affects people from all racial and ethnic groups. Additionally about 3 in 100 people with hemophilia B develop an inhibitor to the treatment product used to treat or prevent their bleeding episodes.
3. As per Santoro, Cristina, et al., 2018, the development of an inhibitor in Hemophilia B is a rare event i.e., 1.5–3% of all patients but is associated with a significant morbidity, related not only to the bleeding risk but also to the frequent occurrence of allergic reactions and nephrotic syndrome.
Key companies working on Hemophilia B that are given below:-
1. Novo Nordisk Pharma Co.
2. CSL Behring Pharma Co.
3. Bioverativ Therapeutics (a Sanofi acquired company)
Drug names are given below:-
1. Rebinyn
2. Idelvion
3. Alprolix
1. Key Insights
2. Executive Summary of Hemophilia B
3. Competitive Intelligence Analysis for Hemophilia B
4. Hemophilia B: Market Overview at a Glance
4.1. Hemophilia B Total Market Share (%) Distribution in 2017
4.2. Hemophilia B Total Market Share (%) Distribution in 2030
5. Hemophilia B: Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Pathophysiology
5.4. Risk Factors
5.5. Diagnosis
6. Patient Journey
7. Hemophilia B Epidemiology and Patient Population
7.1. Epidemiology Key Findings
7.2. Assumptions and Rationale: 7MM
7.3. Epidemiology Scenario: 7MM
7.3.1. Hemophilia B Epidemiology Scenario in the 7MM (2017-2030)
7.4. United States Epidemiology
7.4.1. Hemophilia B Epidemiology Scenario in the United States (2017-2030)
7.5. EU-5 Country-wise Epidemiology
7.5.1. Germany Epidemiology
7.5.1.1. Hemophilia B Epidemiology Scenario in Germany (2017-2030)
7.5.2. France Epidemiology
7.5.2.1. Hemophilia B Epidemiology Scenario in France (2017-2030)
7.5.3. Italy Epidemiology
7.5.3.1. Hemophilia B Epidemiology Scenario in Italy (2017-2030)
7.5.4. Spain Epidemiology
7.5.4.1. Hemophilia B Epidemiology Scenario in Spain (2017-2030)
7.5.5. United Kingdom Epidemiology
7.5.5.1. Hemophilia B Epidemiology Scenario in the United Kingdom (2017-2030)
7.5.6. Japan Epidemiology
7.5.6.1. Hemophilia B Epidemiology Scenario in Japan (2017-2030)
8. Treatment Algorithm, Current Treatment, and Medical Practices
8.1. Hemophilia B Treatment and Management
8.2. Hemophilia B Treatment Algorithm
9. Unmet Needs
10. Key Endpoints of Hemophilia B Treatment
11. Marketed Products
11.1. List of Marketed Products in the 7MM
11.2. Drug Name: Company Name
11.2.1. Product Description
11.2.2. Regulatory Milestones
11.2.3. Other Developmental Activities
11.2.4. Pivotal Clinical Trials
11.2.5. Summary of Pivotal Clinical Trial
List to be continued in report
12. Emerging Therapies
12.1. Key Cross
12.2. Drug Name: Company Name
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Development
12.2.4. Safety and Efficacy
12.2.5. Product Profile
List to be continued in report
13. Hemophilia B: Seven Major Market Analysis
13.1. Key Findings
13.2. Hemophilia B Market Size in 7MM
13.3. Hemophilia B Market Size by Therapies in the 7MM
14. Attribute analysis
15. 7MM: Market Outlook
15.1. United States: Market Size
15.1.1. Hemophilia B Total Market Size in the United States
15.1.2. Hemophilia B Market Size by Therapies in the United States
15.2. EU-5 countries: Market Size and Outlook
15.3. Germany Market Size
15.3.1. Hemophilia B Total Market Size in Germany
15.3.2. Hemophilia B Market Size by Therapies in Germany
15.4. France Market Size
15.4.1. Hemophilia B Total Market Size in France
15.4.2. Hemophilia B Market Size by Therapies in France
15.5. Italy Market Size
15.5.1. Hemophilia B Total Market Size in Italy
15.5.2. Hemophilia B Market Size by Therapies in Italy
15.6. Spain Market Size
15.6.1. Hemophilia B Total Market Size in Spain
15.6.2. Hemophilia B Market Size by Therapies in Spain
15.7. United Kingdom Market Size
15.7.1. Hemophilia B Total Market Size in the United Kingdom
15.7.2. Hemophilia B Market Size by Therapies in the United Kingdom
15.8. Japan Market Outlook
15.8.1. Japan Market Size
15.8.2. Hemophilia B Total Market Size in Japan
15.8.3. Hemophilia B Market Size by Therapies in Japan
16. Access and Reimbursement Overview of Hemophilia B
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
20.1. Bibliography
20.2. Report Methodology
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
- The report will help in developing business strategies by understanding trends shaping and driving the Hemophilia B market
- To understand the future market competition in the Hemophilia B market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Hemophilia B in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Hemophilia B market
- To understand the future market competition in the Hemophilia B market
Related Reports:-
1. Hemophilia B – Pipeline Insights, 2020
2. Hemophilia A – Pipeline Insights, 2020
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/